{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056948","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.249368+00:00","generated_at":"2026-06-02T07:57:22.720115+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lineage Cell Therapeutics Q1 2024: rev $1.4M, net loss $6.5M; new Genentech OpRegen deal","bullets":["Revenue of $1.4M, down from $2.4M YoY; net loss attributable $6.5M ($0.04/sh) vs $4.4M ($0.03/sh).","Cash $43.6M; expected to fund operations into Q3 2025.","New services agreement with Genentech to support OpRegen clinical and manufacturing activities.","OpRegen Phase 1/2a long-term data: mean BCVA gain of 5.5 letters at 24 months in Cohort 4 patients.","OPC1 clinical study start-up underway; received CIRM grant for 2nd Annual SCI Investor Symposium."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056948","json":"https://secwatch.observer/filing/0000950170-24-056948.json","markdown":"https://secwatch.observer/filing/0000950170-24-056948.md","text":"https://secwatch.observer/filing/0000950170-24-056948.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000095017024056948/0000950170-24-056948-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000095017024056948/lctx-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:57:22.720115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"73af017b3b01757599b04a4cacad4b4e957a1315","claim":"Lineage Cell Therapeutics, Inc. reported the quarter ended March 31, 2024 results: revenue $1.4 million.","evidence_excerpt":"Total revenues for the three months ended March 31, 2024 were approximately $1.4 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024056948/0000950170-24-056948-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$1.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}